Madrigal Pharmaceuticals Inc MDGL

US Biotechnology

$467.32 ▼ -5.23% ($-25.79)

Open $490.00

Prev Close $493.11

Day Range $460.11 – $490.23

52W Range $290.00 – $615.00

Market Cap $10.77B

Beta -1.05

EPS (TTM) $-13.63

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2007-02-06
Shares Out.	23,060,000
Website	madrigalpharma.com/ ↗
Phone	13026587581
Employees	915
Revenue	$311.3M
Gross Profit	$284.5M
Net Income	-$94.4M
Free Cash Flow	-$272.4M
Total Assets	$1.23B
Total Liabilities	$683.9M
Equity	$543.5M

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Inc is a publicly traded company under the ticker symbol MDGL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.